Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma Limited has submitted its financial results for the quarter and half-year ended September 30, 2025 to NSE. This is a routine regulatory filing of the company's unaudited/reviewed quarterly financial statements. The detailed financial figures (revenue, profit, margins, segment performance) are not provided in the headline alone and would need to be reviewed from the actual results document. Investors should look at the full results PDF for specific numbers on revenue growth, EBITDA, profit after tax, and debt levels. Piramal Pharma operates across CDMO, critical care, and consumer healthcare segments, and Q2 results will indicate how these businesses are tracking in FY26.
For shareholders, this filing confirms timely disclosure of Q2 FY26 numbers but the actual stock price reaction will depend on the reported financials versus market expectations. No immediate price-moving signal can be determined from the submission notice alone.